2-Cyclopropyl-2-methoxyethan-1-amine | 1488263-56-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Cyclopropyl-2-methoxyethan-1-amine
• 英文别名: 2-cyclopropyl-2-methoxyethanamine
• CAS: 1488263-56-4
• 化学式: C₆H₁₃NO
• 分子量: 115.17
• InChiKey: LPIMNJFSGJOKSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• PYRAZINONE MODULATOR OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY
  申请人：Bristol-Myers Squibb Company

  公开号：EP2303867A1

  公开（公告）日：2011-04-06
• SUBSTITUTED CARBAMATE DERIVATIVES AS MODULATORS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY
  申请人：Bristol-Myers Squibb Company

  公开号：EP2307024A1

  公开（公告）日：2011-04-13
• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GlaxoSmithKline Intellectual Property (No. 2) Limited

  公开号：EP3221317A1

  公开（公告）日：2017-09-27
• [EN] PYRAZINONE MODULATOR OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY<br/>[FR] MODULATEUR PYRAZINONE DE L'ACTIVITÉ DE LA CORTICOLIBÉRINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2010014280A1

  公开（公告）日：2010-02-04

  The invention relates to the compound (S)~4»(l-cyclopropyl-2-methoxyethyl)- 6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylatnino)-5-oxo-4,5-dihydropyrazine- 2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF.
• [EN] SUBSTITUTED CARBAMATE DERIVATIVES AS MODULATORS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY<br/>[FR] DÉRIVÉS DE CARBAMATE SUBSTITUÉS EN TANT QUE MODULATEURS DE L'ACTIVITÉ DU RÉCEPTEUR DE FACTEUR DE LIBÉRATION DE CORTICOTROPINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2010014687A1

  公开（公告）日：2010-02-04

  The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds are CRF receptor antagonists and may be useful for treating disorders associated with abnormal CRF levels or aberrant functioning of CRF receptors.